Correlation Between Vertex Pharmaceuticals and Dogwood Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Vertex Pharmaceuticals and Dogwood Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vertex Pharmaceuticals and Dogwood Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vertex Pharmaceuticals and Dogwood Therapeutics,, you can compare the effects of market volatilities on Vertex Pharmaceuticals and Dogwood Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vertex Pharmaceuticals with a short position of Dogwood Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vertex Pharmaceuticals and Dogwood Therapeutics,.

Diversification Opportunities for Vertex Pharmaceuticals and Dogwood Therapeutics,

0.36
  Correlation Coefficient

Weak diversification

The 3 months correlation between Vertex and Dogwood is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Vertex Pharmaceuticals and Dogwood Therapeutics, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dogwood Therapeutics, and Vertex Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vertex Pharmaceuticals are associated (or correlated) with Dogwood Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dogwood Therapeutics, has no effect on the direction of Vertex Pharmaceuticals i.e., Vertex Pharmaceuticals and Dogwood Therapeutics, go up and down completely randomly.

Pair Corralation between Vertex Pharmaceuticals and Dogwood Therapeutics,

Given the investment horizon of 90 days Vertex Pharmaceuticals is expected to generate 2.66 times less return on investment than Dogwood Therapeutics,. But when comparing it to its historical volatility, Vertex Pharmaceuticals is 6.51 times less risky than Dogwood Therapeutics,. It trades about 0.07 of its potential returns per unit of risk. Dogwood Therapeutics, is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  623.00  in Dogwood Therapeutics, on September 12, 2024 and sell it today you would lose (349.00) from holding Dogwood Therapeutics, or give up 56.02% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Vertex Pharmaceuticals  vs.  Dogwood Therapeutics,

 Performance 
       Timeline  
Vertex Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Vertex Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Vertex Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.
Dogwood Therapeutics, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Dogwood Therapeutics, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Vertex Pharmaceuticals and Dogwood Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Vertex Pharmaceuticals and Dogwood Therapeutics,

The main advantage of trading using opposite Vertex Pharmaceuticals and Dogwood Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vertex Pharmaceuticals position performs unexpectedly, Dogwood Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dogwood Therapeutics, will offset losses from the drop in Dogwood Therapeutics,'s long position.
The idea behind Vertex Pharmaceuticals and Dogwood Therapeutics, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance